166 / 172
166
combined, in patients with active rheumatoid arthritis despite
receiving sulfasalazine: a double-blind comparison. Ann
Rheum Dis 2006;65:1357-62.
168.Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP,
Kvien TK, et al. Efficacy, safety and patient-reported outcomes
of combination etanercept and sulfasalazine versus etanercept
alone in patients with rheumatoid arthritis: a double-blind
randomised 2-year study. Ann Rheum Dis 2009; 68: 1146-52.
169.Klareskog L, van der Heijde D, de Jager JP, Gough A,
Kalden J, Malaise M, et al. Therapeutic effect of the
combination of etanercept and methotrexate compared with
each treatment alone in patients with rheumatoid arthritis:
double-blind randomised controlled trial. Lancet 2004;363:675-
81.
170.van der Heijde D, Burmester G, Melo-Gomes J, Codreanu
C, Mola EM, Pedersen R, et al. The safety and efficacy of
adding etanercept to methotrexate or methotrexate to
etanercept in moderately active rheumatoid arthritis patients
previously treated with monotherapy. Ann Rheum Dis
2008;67:182-8.
171.Kavanaugh A, Klareskog L, van der Heijde D, Li J,
Freundlich B, Hooper M. Improvements in clinical response
between 12 and 24 weeks in patients with rheumatoid arthritis
on etanercept therapy with or without methotrexate. Ann
Rheum Dis 2008;67:1444-7.
172.Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise
M, Dougados M, Wajdula J. A long-term, open-label trial of
the safety and efficacy of etanercept (Enbrel) in patients with
rheumatoid arthritis not treated with other disease-modifying
antirheumatic drugs. Ann Rheum Dis 2006;65:1578-84.
173.Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise
M, Dougados M, Wajdula J. Assessment of long-term safety
and efficacy of etanercept in a 5-year extension study in